Literature DB >> 6145101

Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat.

A Hedberg, H Mattsson, V Nerme, E Carlsson.   

Abstract

The full agonist isoprenaline (5.3-6.6 nmol/kg . min) and the partial beta-adrenoceptor agonist prenalterol (10.6-13.3 nmol/kg . min) were administered to cats continuously via osmotic minipumps (i.p.). After seven days the functional and adenylate cyclase responsiveness to the agonists, as well as the beta-adrenoceptor-binding characteristics, were studied in cardiac and soleus muscle preparations in vitro. After isoprenaline pretreatment, the papillary muscles and soleus muscle strips wer 15-18 times less sensitive to isoprenaline compared with muscles from control cats. The stimulatory potency (pD2) of prenalterol in the papillary muscle was not changed significantly. The affinity of the agonists to the beta-adrenoceptors was unaffected in both tissues by the pretreatment, but the densities of beta-adrenoceptors were significantly reduced, by 36% (myocardium) and 47% (soleus) respectively. In the cat papillary muscle the intrinsic sympathomimetic activity (ISA) of prenalterol on contractile parameters was reduced from 84 (Tmax), 69 (dT/dtmax) and 71% (dT/ dtmin ) in control animals, to 33, 22 and 28%, respectively in the animals pretreated with isoprenaline. Prenalterol pretreatment did not induce any marked changes, either in the stimulatory potency or affinity of the agonists in the two tissues or in the maximal response (ISA) of prenalterol in the papillary muscle. The marked reduction in the stimulatory potency of isoprenaline and the reduced ISA of prenalterol in the myocardium after isoprenaline pretreatment can not be explained by the reduction in beta- adrenoceptor density alone. Since the affinity to the beta- adrenoceptors is unaffected, a reduced efficiency in the signal transmission must be the main cause.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145101     DOI: 10.1007/bf00495952

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  An in vitro method for the study of beta-receptor mediated effects on slow contracting skeletal muscle.

Authors:  B Waldeck
Journal:  J Pharm Pharmacol       Date:  1976-05       Impact factor: 3.765

2.  Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes.

Authors:  K P Minneman; L R Hegstrand; P B Molinoff
Journal:  Mol Pharmacol       Date:  1979-07       Impact factor: 4.436

3.  Convenient apparatus for recording contractions of isolated heart muscle.

Authors:  J R Blinks
Journal:  J Appl Physiol       Date:  1965-07       Impact factor: 3.531

4.  Beta-adrenergic receptor subtypes: properties, distribution, and regulation.

Authors:  K P Minneman; R N Pittman; P B Molinoff
Journal:  Annu Rev Neurosci       Date:  1981       Impact factor: 12.449

5.  In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure.

Authors:  T P Kenakin; D Beek
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

6.  High efficiency coupling between beta-adrenergic receptors and cardiac contractility: direct evidence for "spare" beta-adrenergic receptors.

Authors:  J C Venter
Journal:  Mol Pharmacol       Date:  1979-09       Impact factor: 4.436

7.  Beta adrenoceptor interaction of full and partial agonists in the cat heart and soleus muscle.

Authors:  A Hedberg; H Mattsson
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

8.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

9.  Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats.

Authors:  H Y Chang; R M Klein; G Kunos
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

10.  Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol.

Authors:  T P Kenakin; R M Ferris
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

View more
  5 in total

Review 1.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 2.  Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue.

Authors:  Y T Yang; M A McElligott
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

3.  A physiological basis for subclassifying beta-adrenoceptors examined by chemical sympathectomy of guinea-pigs.

Authors:  K J Broadley; R G Chess-Williams; P F Grassby
Journal:  J Physiol       Date:  1986-04       Impact factor: 5.182

4.  Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

Review 5.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.